Navigation Links
Dipexium Pharmaceuticals Reaches 75% Enrollment Milestone in Pivotal Phase 3 Clinical Trials
Date:2/4/2016

NEW YORK, Feb. 4, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today announced its OneStep-1 and OneStep-2 pivotal Phase 3 clinical trials have reached the 75% enrollment milestone, in the aggregate, with each study having enrolled nearly the same number of patients. OneStep-1 and OneStep-2 are identical, pivotal Phase 3 clinical trials (180 patients per clinical trial) being conducted under a Special Protocol Assessment (SPA) agreement between the U.S. Food and Drug Administration and Dipexium for evaluation of Locilex® for the treatment of patients with mild infections of diabetic foot ulcers.

The Company anticipates completing these trials in the second half of 2016 and is targeting a New Drug Application (NDA) submission with the U.S. Food and Drug Administration in the first half of 2017 and a Marketing Authorization Application (MAA) submission with the European Medicines Agency in the second half of 2017. More information about the OneStep-1 and OneStep-2 pivotal Phase 3 clinical trials is available at www.clinicaltrials.gov<http://www.clinicaltrials.gov>.

About Dipexium Pharmaceuticals, Inc.

Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX) is a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical antibiotic peptide. Initially, Locilex® is targeted for the treatment of mild infections of diabetic foot ulcers. Based on a compilation of available clinical and microbiology data, Locilex® is also considered a promising product candidate to treat other mild and moderate skin and skin structure infections, including infected decubitus ulcers, infected burns, infected surgical wounds and nasal colonization of methicillin-resistant staphylococcus aureus (MRSA).

Cautionary Note on Forward-Looking Statements

This press release and any statements of representatives and partners of Dipexium Pharmaceuticals, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the U.S. federal securities laws.  Such forward-looking statements involve significant risks and uncertainties.  Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions.  These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission and those that relate to the Company's ability to leverage the expertise of employees and partners to assist the Company in the execution of its strategy.  Actual results (including, without limitation, the timing for and results of the clinical trials and proposed NDA submission for Locilex®) may differ significantly from those set forth in the forward-looking statements.  These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Company Contacts:

David P. Luci
President & Chief Executive Officer
Dipexium Pharmaceuticals, Inc.
212-269-2834
info@dipexium.com

David Garrett
Vice President, Finance & Corporate Development
Dipexium Pharmaceuticals, Inc.
212-269-2834
info@dipexium.com

© 2016 Dipexium Pharmaceuticals, Inc.  All rights reserved.


'/>"/>
SOURCE Dipexium Pharmaceuticals, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Dipexium Pharmaceuticals Reports Second Quarter 2014 Financial and Operational Results
2. Dipexium Pharmaceuticals Reports Third Quarter 2014 Financial and Operational Results
3. Dipexium Pharmaceuticals to Present at Jefferies 2015 Antibiotic Summit
4. Dipexium Pharmaceuticals to Hold Year End 2014 Financial Results Conference Call on Tuesday, March 24, 2015, 8:30 a.m. ET
5. Dipexium Pharmaceuticals Reports 2014 Financial Results
6. Dipexium Pharmaceuticals to Hold First Quarter 2015 Financial Results Conference Call on Thursday, May 14, 2015, at 8:30 a.m. ET
7. Dipexium Pharmaceuticals Reports First Quarter 2015 Financial Results
8. Dipexium Announces Presentation at 7th International Symposium on the Diabetic Foot
9. Dipexium annonce une présentation lors du 7e International Symposium on the Diabetic Foot
10. Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an
11. Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2019)... , ... April 18, 2019 , ... ... compensation industry, today announced it has been invited to participate in the inaugural ... which will be coming to Boston April 28th through May 1st. ...
(Date:4/18/2019)... ... April 18, 2019 , ... ... (FMA). The FMA is one of the country’s premier professional associations dedicated to ... in Florida. The FMA currently represents over 25,000 members on issues of legislation ...
(Date:4/18/2019)... ... April 18, 2019 , ... ... by Sleep Outfitters and Tempur Sealy, at Fasig-Tipton horse farm on May 17, ... Located in the heart of the Bluegrass, this elegant venue highlights Kentucky's stunning ...
Breaking Medicine Technology:
(Date:4/19/2019)... ... April 19, 2019 , ... Elohi Strategic ... and eco-friendly foodservice brands. From plant-based proteins to herbal tonics, gluten-free pastas to ... , • Field Roast, a Seattle-based company, is the ...
(Date:4/18/2019)... SOMERSET, N.J. (PRWEB) , ... April 18, 2019 ... ... today announced a number of workshop presentations at the upcoming Global Clinical Supplies ... & Spa, San Antonio, Texas, on April 28 – May 1, 2019. , ...
(Date:4/18/2019)... ... 2019 , ... Swiss Pet company PerAnimal launches a new unique ... between human and animal while improving the overall wellness of pet companions. , All ... of experience. They are made by hand from organic Swiss herbal condensate and Swiss ...
(Date:4/18/2019)... ... April 18, 2019 , ... Governor Phil Scott signed new ... year’s bill proposed several updates to Vermont’s leading captive law, including modifications to ... The many enhancements included in this year’s bill highlight the state’s ability to ...
(Date:4/18/2019)... (PRWEB) , ... April 18, 2019 , ... She went ... a pair of eyeglasses, said her mother, Cheryl Reilly. Those “goofy tests,” performed by ... that Mikayla Reilly, then 12 years old, had such narrow range of visual awareness, ...
Breaking Medicine News(10 mins):